First investigational drug therapy for liver disease NASH awaiting FDA approval
Patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease and a leading cause for liver transplantation in the U.S., currently lack an approved drug therapy, but this may soon change. A large Phase III clinical ...
Dec 5, 2019
0
6